Asia's Nasdaq? Hong Kong‘s Quest To Be IPO Power House Has Blessings And Curses
Executive Summary
Hundreds of executives showed up at an inaugural biotech summit organized by the Hong Kong Stock Exchange, setting the stage for a showdown between the territory and the most popular destination for biotech IPOs, Nasdaq in the US. Despite recent rule changes to allow pre-revenue biotechs to gain a listing more easily, executives still see hurdles that are associated with Hong Kong's close proximity to the very market it is trying to allure, mainland China.
You may also be interested in...
Finance Watch: Lots Of Money, Big And Small, Flowing Into Drug Development
Big venture capital bets continue in biopharma, including Foresite's new $668m fund and Merck's $125m investment in Moderna, but small VC rounds could be making a comeback. In public company financings, Aslan and Evelo launched in the US, while Ascletis is testing Hong Kong’s IPO market.
IPO Update: Will Declining Returns Slow Fast Pace Of Biopharma Offerings?
Offerings by Homology, Unum and Genprex at the end of March brought the first quarter's biopharma IPO total to 14 in the US, putting 2018 on track to beat the 2017 total of 42. But with the average return for this year's IPOs dropping, the pace of offerings could slow.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.